PBAE Nanoparticles for Retinal Gene Editing Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene editing technologies, such as CRISPR/Cas9, face challenges in delivering gene editing factors efficiently to cells, particularly for treating retinal eye diseases, due to limitations in transfection efficacy and safety of viral vectors.
Innovation Solution
Development of biodegradable poly(beta-amino ester) (PBAE) nanoparticles that self-assemble with nucleic acids encoding gene-editing proteins, allowing for efficient site-specific gene disruption and modification, including the use of CRISPR/Cas9 and guide RNA, to facilitate gene editing and therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used to deliver gene editing factors, then transfection efficacy is improved, but safety concerns and immunogenicity increase
Solution Approach 1:
The patent introduces PBAE nanoparticles as an intermediary delivery vehicle between the gene editing factors (Cas9, sgRNA) and the target cells. These non-viral nanoparticles mediate the delivery process, achieving effective transfection while avoiding the safety issues and immunogenicity associated with viral vectors. The nanoparticles serve as a safe intermediary that can be engineered to control release and target specific cells.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of PBAE polymers, including variations in molecular weight, composition, and functional groups. By adjusting these parameters, the nanoparticles achieve optimal transfection efficacy while maintaining safety profiles superior to viral vectors. The ability to tune polymer parameters allows optimization of both delivery efficiency and biocompatibility.
2Object-affected harmful factors
If non-viral delivery vehicles are used to improve safety, then immunogenicity is reduced, but transfection efficacy deteriorates
Solution Approach 1:
The patent systematically varies key parameters of the PBAE polymers including molecular weight (5kDa to 50kDa), composition ratios of different monomers, and functional group densities. These parameter changes enable the non-viral nanoparticles to achieve transfection efficacy comparable to or exceeding viral vectors while maintaining the safety advantages of non-viral systems. The optimized parameters balance cellular uptake efficiency with reduced immunogenicity.
Solution Approach 2:
The patent utilizes composite PBAE nanoparticle formulations combining multiple polymer components with complementary properties. These composite materials integrate the benefits of different polymer types to achieve both high transfection efficacy and low immunogenicity. The composite structure allows synergistic effects where one component enhances cellular uptake while another reduces immune recognition.
3Productivity
If poly(beta-amino ester) nanoparticles are designed with higher molecular weight, then transfection efficacy is improved, but cytotoxicity increases
Solution Approach 1:
The patent carefully optimizes the molecular weight parameter of PBAE polymers within a specific range (5kDa to 50kDa). This parameter optimization achieves the critical balance where higher molecular weight provides improved transfection efficacy through better cellular uptake and endosomal escape, while remaining below the threshold that triggers significant cytotoxicity. The identified optimal range represents a narrow window where both objectives are satisfied.
Solution Approach 2:
The patent applies partial action by using molecular weights that are sufficiently high to achieve effective transfection but deliberately not excessively high to avoid cytotoxicity. The molecular weight is optimized to the minimum level required for effective gene delivery, avoiding the diminishing returns and increased toxicity associated with higher molecular weights. This partial optimization strategy achieves the necessary transfection efficacy without excessive molecular weight-induced harm.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PBAE nanoparticles demonstrate enhanced transfection efficacy and safety, achieving significant gene editing in retinal cells, including hereditary retinal eye diseases like age-related macular degeneration and Leber's congenital amaurosis, with improved delivery and reduced cytotoxicity compared to traditional methods.
Implementation Method 1
biodegradable poly(beta-amino ester) (PBAE) nanoparticles that self-assemble with nucleic acids
Data Source
AI summary
Biodegradable particles for delivering a nucleic acid encoding gene-editing factors or a nucleic acid associated with a therapeutic protein to a cell, and compositions, methods, systems, and kits for gene editing in vivo or ex vivo or gene therapy for treating retinal eye diseases are disclosed.